Arbour et al. identified different biological subtypes of KRAS-mutant lung adenocarcinoma that could be associated with co-mutations and investigated the effect of co-mutations on patient prognosis and treatment response. The gene discussed is KRAS; the disease is lung adenocarcinoma.